全文获取类型
收费全文 | 60013篇 |
免费 | 6580篇 |
国内免费 | 2248篇 |
专业分类
耳鼻咽喉 | 127篇 |
儿科学 | 550篇 |
妇产科学 | 224篇 |
基础医学 | 2448篇 |
口腔科学 | 387篇 |
临床医学 | 5189篇 |
内科学 | 6745篇 |
皮肤病学 | 1043篇 |
神经病学 | 2012篇 |
特种医学 | 607篇 |
外国民族医学 | 7篇 |
外科学 | 1732篇 |
综合类 | 7914篇 |
现状与发展 | 5篇 |
一般理论 | 3篇 |
预防医学 | 3600篇 |
眼科学 | 641篇 |
药学 | 29072篇 |
26篇 | |
中国医学 | 2909篇 |
肿瘤学 | 3600篇 |
出版年
2024年 | 68篇 |
2023年 | 967篇 |
2022年 | 1158篇 |
2021年 | 2016篇 |
2020年 | 2202篇 |
2019年 | 2217篇 |
2018年 | 2265篇 |
2017年 | 2539篇 |
2016年 | 2353篇 |
2015年 | 2366篇 |
2014年 | 4011篇 |
2013年 | 6772篇 |
2012年 | 4109篇 |
2011年 | 4192篇 |
2010年 | 3372篇 |
2009年 | 2989篇 |
2008年 | 2803篇 |
2007年 | 2842篇 |
2006年 | 2560篇 |
2005年 | 2303篇 |
2004年 | 1958篇 |
2003年 | 1790篇 |
2002年 | 1361篇 |
2001年 | 1317篇 |
2000年 | 997篇 |
1999年 | 848篇 |
1998年 | 722篇 |
1997年 | 675篇 |
1996年 | 566篇 |
1995年 | 549篇 |
1994年 | 467篇 |
1993年 | 395篇 |
1992年 | 452篇 |
1991年 | 378篇 |
1990年 | 300篇 |
1989年 | 242篇 |
1988年 | 243篇 |
1987年 | 236篇 |
1986年 | 183篇 |
1985年 | 195篇 |
1984年 | 160篇 |
1983年 | 123篇 |
1982年 | 105篇 |
1981年 | 85篇 |
1980年 | 58篇 |
1979年 | 57篇 |
1978年 | 67篇 |
1977年 | 46篇 |
1976年 | 47篇 |
1975年 | 48篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
54.
Carmil Azran Daniel Porat Noa Fine-Shamir Nirvana Hanhan Arik Dahan 《Surgery for obesity and related diseases》2019,15(2):333-341
Background
Bariatric surgery can lead to changes in the oral absorption of many drugs. Levothyroxine is a narrow therapeutic drug for hypothyroidism, a common condition among patients with obesity.Objective
The purpose of this work was to provide a mechanistic overview of levothyroxine absorption, and to thoroughly analyze the expected effects of bariatric surgery on oral levothyroxine therapy.Methods
We performed a systematic review of the relevant literature reporting the effects of bariatric surgery on oral levothyroxine absorption and postoperative thyroid function. A PubMed search for relevant keywords resulted in a total of 14 articles reporting levothyroxine status before versus after bariatric surgery.Results
Different mechanisms may support opposing trends as to levothyroxine dose adjustment postsurgery. On the one hand, based on impaired drug solubility/dissolution attributable to higher gastric pH as well as reduced gastric volume, compromised levothyroxine absorption is expected. On the other hand, the great weight loss, and altered set-point of thyroid hormone homeostasis with decreased thyroid-stimulating hormone after the surgery, may result in a decreased dose requirement.Conclusions
For patients after bariatric surgery, close monitoring of both the clinical presentation and plasma thyroid-stimulating hormone and T4 levels is strongly advised. Better understanding and awareness of the science presented in this article may help to avoid preventable complications and provide optimal patient care. 相似文献55.
目的优化丁香苦苷聚乳酸(Syr)-羟基乙酸共聚物[poly(lactic-co-glycolic acid),PLGA]纳米粒(Syr-NPs)的处方。方法采用纳米沉淀法制备Syr-NPs,以包封率、载药量、平均粒径以及总评"归一值"为评价指标,采用星点设计-效应面法考察PLGA质量浓度(A)、丁香苦苷质量浓度(B)、水相与有机相比例(C)3因素考察对包封率、载药量、平均粒径以及总评归一值的影响,以星点设计-效应面法选取最佳处方条件进行预测分析。结果最优处方工艺为PLGA质量浓度为9.63 mg/mL,Syr质量浓度为12.88 mg/mL,有机相与水相的比例为1∶9.46,制得的Syr-NPs的包封率、载药量、平均粒径分别为(27.86±0.87)%、(7.02±0.15)%、(110.0±1.20)nm。结论该方法稳定可行,可用于优化包载Syr的PLGA纳米粒处方与制备工艺。 相似文献
56.
张晨 《中华整形外科杂志》2021,(2)
肉毒毒素注射引起的不良反应,是药物本身的组成成分引起的与用药目的无关的有害反应,与医生注射方式和注射技术无关。尽管肉毒毒素生产厂家的药品说明书上也有提示,但其所提供的信息不够全面,也未必能引起医生的足够重视。目前文献上多为散发病例。为此作者对过去20年有关肉毒毒素注射引起的过敏反应、肉瘤样肉芽肿、眼睑水肿、流感样症状等相关不良反应的临床表现、发病机制与治疗方法进行综述。 相似文献
57.
Erin M. Corsini Wayne L. Hofstetter 《The Journal of thoracic and cardiovascular surgery》2021,161(2):448-454
ObjectivesRecent evidence has shown an association between postoperative ketorolac use and anastomotic leak in patients undergoing intestinal and colorectal operations, but this relationship has been minimally explored after esophagectomy. As the use of nonopioid pain control and enhanced recovery protocols is increasingly prioritized, determination of a possible correlation between perioperative ketorolac use and leak is essential.MethodsRecords of patients undergoing esophagectomy for adenocarcinoma at a single institution from 2006 to 2018 reviewed for occurrence of anastomotic leak. Institutional pharmacy records were queried for ketorolac administration during the surgical case through the time of discharge. Multivariable logistic regression was used to determine the relationship between ketorolac administration and anastomotic leak.ResultsA total of 1019 patients met inclusion criteria, the majority of whom were male (907, 89%) with a median age of 62 years. Patients predominantly presented with locoregionally advanced disease and were treated with initial chemoradiation. Ketorolac was administered to 686 patients (67%); use was observed to increase over the study period from 49% in 2006 to 92% in 2016. Conversely, anastomotic leak occurred in 87 patients (9%) overall and decreased over time from 15% (11/72) in 2006 to 2% (2/83) in 2018. Upon multivariable analysis, neither ketorolac administration evaluated as a categoric variable (odds ratio, 0.99; P = .958) or as a continuous variable using dose (odds ratio, 1.00; P = .843) demonstrated an association with anastomotic leak.ConclusionsKetorolac in the postoperative period after esophagectomy has become an integral component of enhanced recovery pathways and does not appear to be associated with anastomotic leak. 相似文献
58.
59.
Biologics are efficacious for treating psoriasis vulgaris (PsV) and psoriatic arthritis (PsA), but sometimes must be terminated or changed for various reasons including ineffectiveness or adverse events. To find the optimal choice of biologics for treating psoriasis, we analyzed the real‐world data on drug survival and the reason for terminating or switching biologics. Medical records from patients with PsV or PsA, who visited the Department of Dermatology, Fukuoka University Hospital from 2010 to 2017, were analyzed. Two hundred and eleven patients received biologics, and 147 patients (69.7%) were treated with only one biologic, while 64 patients (30.3%) were switched to different products. Frequently used biologics in PsV were ustekinumab (UST), infliximab and adalimumab when calculated by patient‐year. Tumor necrosis factor inhibitor (TNFi) use decreased while UST and interleukin (IL)‐17 inhibitors increased in newly introduced patients. UST showed the highest survival rate as a first‐line drug, but the advantage was lost in the second reagent's group. The major reasons for terminating/switching biologics were as follows: primary ineffectiveness (26.4%), secondary loss of efficacy (36.5%), patient's preference, including referral to nearby hospital, or stopped visiting (22.6%), side‐effects (7.7%), comorbidities (3.4%) and economic burden (2.4%). In PsA patients, TNFi are more frequently employed than in PsV patients, although switching to UST or IL‐17 inhibitors showed an increasing trend. Biologic reagents were changed mostly because of primary or secondary loss of efficacy, which affected drug survival. Further research is needed to find the optimal choice of biologics with larger samples at multiple facilities. 相似文献